news – Page 15 – Medxy AI

Rising Trends into Transcatheter Aortic Valve Reinterventions: Redo TAVR and Explant Procedures from 2012 to 2024

By MedXY 09/27/2025

This article reviews increasing volumes and incidence of transcatheter aortic valve replacement (TAVR) reinterventions, analyzing procedural trends of redo TAVR and TAVR explant over the past decade, emphasizing implications for clinical practice and future strategies.

Cardiology Clinical Updates news

Systolic Blood Pressure as a Key Modifier of Survival Benefit from Microaxial Flow Pump Therapy in Infarct-Related Cardiogenic Shock: Insights from the DanGer Shock Trial

By MedXY 09/27/2025

This post hoc analysis of the DanGer Shock trial reveals that low systolic blood pressure at treatment initiation markedly enhances survival benefit from microaxial flow pump support in infarct-related cardiogenic shock.

Diabetes & Endocrinology news Specialties

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

By MedXY 09/27/2025

Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies.

General Surgery Neurology news

Efficacy and Safety of Shunt Surgery in Idiopathic Normal-Pressure Hydrocephalus: Insights from a Rigorous Randomized Controlled Trial

By MedXY 09/27/2025

A double-blind, placebo-controlled trial demonstrates that shunt surgery significantly improves gait velocity and balance in patients with idiopathic normal-pressure hydrocephalus who respond to temporary CSF drainage, with mixed safety outcomes and no cognitive or urinary symptom benefits at 3 months.

Infectious Diseases news Pediatrics Respiratory Specialties

Clesrovimab: A Promising Monoclonal Antibody for Preventing RSV in Healthy Infants

By MedXY 09/27/2025

A single dose of clesrovimab significantly reduces respiratory syncytial virus (RSV) infections and hospitalizations in healthy infants during their first RSV season, with a safety profile comparable to placebo.

Clinical Updates Hematology-Oncology news

Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy

By MedXY 09/26/2025

Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocytic leukemia.

Cardiology Clinical Updates Internal Medicine news

Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors

By MedXY 09/26/2025

A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.

Clinical Updates Neurology news

Nexiguran Ziclumeran Gene Editing: A Pioneering Treatment for Hereditary ATTR with Polyneuropathy

By MedXY 09/26/2025

Nexiguran ziclumeran, an innovative CRISPR-Cas9 gene-editing therapy, demonstrates rapid, sustained suppression of transthyretin (TTR) in hereditary ATTR polyneuropathy patients, showing promising late-phase clinical safety and efficacy.

Gastroenterology news

Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults

By MedXY 09/26/2025

Cendakimab, a monoclonal antibody targeting IL-13, shows significant improvements in symptoms, histologic response, and endoscopic features in eosinophilic esophagitis, with a tolerable safety profile through 48 weeks.

Family Medicine & Nutrition Neurology news Specialties

Circulating Nanoparticles and Carotenoids as Biomarkers of Rehabilitation Recovery in Parkinson’s Disease

By MedXY 09/26/2025

Intensive treadmill rehabilitation in Parkinson's disease alters the biochemical composition of circulating extracellular vesicle-like particles, particularly increasing carotenoid content, which correlates with improved gait parameters, highlighting a potential biomarker for monitoring rehabilitation efficacy.

Clinical Updates General Surgery Neurology news Specialties

Minimally Invasive Surgery versus Medical Management for Supratentorial Intracerebral Hemorrhage: Insights from the MIND Trial

By MedXY 09/26/2025

The MIND trial compared minimally invasive surgery using the Artemis device to standard medical management for supratentorial intracerebral hemorrhage, finding no significant improvement in 180-day functional outcomes or 30-day mortality with surgery.

General Surgery Neurology news Specialties

Minimally Invasive Surgery vs Medical Management in Supratentorial Intracerebral Hemorrhage: Insights from the MIND Randomized Trial

By MedXY 09/26/2025

The MIND trial found no significant functional benefit or mortality reduction with minimally invasive surgery compared to medical management alone in supratentorial intracerebral hemorrhage patients at 180 days.

Clinical Updates Diabetes & Endocrinology news

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes

By MedXY 09/26/2025

The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.

Neurology news

Sustained Symptom Control over Five Years: Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson Disease

By MedXY 09/26/2025

Five-year follow-up from the INTREPID trial confirms that subthalamic nucleus deep brain stimulation significantly improves motor symptoms, reduces dyskinesia, lowers medication needs, and enhances daily living activities in moderate to advanced Parkinson disease patients, with an acceptable safety profile.

Clinical Updates Neurology news

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease

By MedXY 09/26/2025

This international trial demonstrates that personalized adaptive deep brain stimulation (aDBS) is a safe, effective, and well-tolerated long-term therapy for Parkinson's disease patients previously stable on continuous DBS.

news Psychiatry

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

By MedXY 09/25/2025

Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.

Clinical Updates Family Medicine & Nutrition news Specialties

Do Oily Fish Intake Increase Pancreatic Cancer Risk?

By MedXY 09/25/2025

This Mendelian randomization study reveals a surprising association between higher oily fish consumption and increased pancreatic cancer risk, highlighting new directions for dietary guidance and pancreatic disease prevention.

Clinical Updates news OB/GYN & Women's Health Oncology

Chemoradiotherapy Enhances Long-Term Survival in High-Risk Endometrial Cancer

By MedXY 09/25/2025

The PORTEC-3 trial demonstrates that adding platinum-based chemotherapy to pelvic radiotherapy significantly improves 10-year overall and recurrence-free survival in high-risk endometrial cancer, especially in patients with p53 abnormal tumors, emphasizing the importance of molecular profiling.

Clinical Updates Diabetes & Endocrinology Neurology news Specialties

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction

By MedXY 09/25/2025

Recent real-world data suggest GLP-1 receptor agonists and SGLT2 inhibitors may lower Alzheimer’s disease risk more effectively than DPP-4 inhibitors, highlighting the need for randomized trials to confirm potential neuroprotective benefits.

Clinical Updates Gastroenterology news

Decoding the Role of Reflux Secondary Bile Acids in Barrett’s Esophagus: Microbiome and Transcriptome Insights

By MedXY 09/25/2025

This study reveals that elevated reflux secondary bile acids in Barrett's esophagus influence the esophageal microbiome and gene expression, highlighting potential mechanisms underpinning progression to esophageal adenocarcinoma.